REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks."
Q1-FY23 Financial Highlights:
- Revenue totaled $2.1 million.
- Gross profit totaled $1.2 million.
- Gross profit margins were 60% and consistent with the full year FY22.
- Net loss totaled $5 million or $0.098 per share; adjusted loss per share, a non- GAAP measure, was $0.085 per share after removing certain non-recurring expenses.
Operating Highlights for the FY22 to Date:
- After receiving FDA 510(k) clearance in January 2022, in April 2022, Biotricity officially launched wireless wearable holter patch device, Biotres, a revolutionary holter technology.
- Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem.
- Launched Bioheart, one of the first heart rhythm recorders and personal heart lifestyle solutions.
- Expanded our network to cover 29 states with over 2,000 physicians using our product.
Full details of the Company's financial results will be filed with the SEC on Form 10-Q by visiting www.sec.gov.
Financial Results Conference Call
Management will host a conference call on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter and provide a business update. Additional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/
Event: | Biotricity Fiscal First Quarter 2023 Financial Results Conference Call |
Date: | Monday, August 15, 2022 |
Time: | 4:30 p.m. Eastern Time |
Live Call: | 1-888-220-8451 (U.S. Toll-Free) or 1-646-828-8193 (International) |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1561778&tp_key=c6d6c779d3 |
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 29, 2022 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 2688378.
About Biotricity:
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward Looking Statements:
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Use of Non-GAAP Information
In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP in this press release, Biotricity presents adjusted net loss, which is a non-GAAP financial measure. Adjusted net loss is determined by deducting one-time derivative fair value and accretion expenses from net loss attributable to common shareholders. Our definition of adjusted net loss may not be comparable to the definitions of similarly titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management.
The following reconciliation calculates the adjusted loss per share:
| 3 months ended June 30, 2022 | ||||
| $ | ||||
Net loss attributable to common stockholders | (5,024,389 | ) | ||
Add: | ||||
Provision for income taxes | - | |||
Interest expense | 388,388 | |||
Depreciation expense | 1,488 | |||
EBITDA | (4,634,512 | ) | ||
Add (Less) | ||||
Other (income) expense related to convertible note conversion | 50,908 | |||
Fair value change on derivative liabilities | 198,224 | |||
Adjusted EBITDA | (4,385,381 | ) | ||
Weighted average number of common shares outstanding | 51,440,944 | |||
Adjusted Loss per Share, Basic and Diluted | (0.085 | ) | ||
Contacts:
Investor Relations:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
investors@biotricity.com
Media Relations:
Erica Fiorini, Russo Partners
(212) 845-4253
Erica.Fiorini@russopartnersllc.com
BIOTRICITY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT JUNE 30, 2022 (unaudited) AND MARCH 31, 2022 (audited)
(Expressed in US Dollars)
| As at June 30, 2022 | As at March 31, 2022 | |||||||
| $ | $ | |||||||
CURRENT ASSETS | ||||||||
Cash | 7,207,974 | 12,066,929 | ||||||
Accounts receivable, net | 1,826,920 | 2,006,678 | ||||||
Inventory | 1,431,054 | 842,924 | ||||||
Deposits and other receivables | 380,592 | 406,280 | ||||||
Total current assets | 10,846,540 | 15,322,811 | ||||||
Deposits | 85,000 | 85,000 | ||||||
Long-term accounts receivable | - | - | ||||||
Property and equipment | 25,970 | 27,459 | ||||||
Operating right-of-use lease asset [Note 10] | 1,192,169 | 1,242,700 | ||||||
TOTAL ASSETS | 12,149,679 | 16,677,970 | ||||||
CURRENT LIABILITIES | ||||||||
Accounts payable and accrued liabilities [Note 4] | 2,701,077 | 2,595,747 | ||||||
Convertible promissory notes and short term loans [Note 5] | 1,238,000 | 1,540,000 | ||||||
Derivative liabilities [Note 8] | 419,332 | 520,747 | ||||||
Operating lease liability [Note 10] | 219,033 | 210,320 | ||||||
Total current liabilities | 4,577,442 | 4,866,814 | ||||||
Federally guaranteed loans [Note 7] | 870,800 | 870,800 | ||||||
Term loan [Note 6] | 11,662,742 | 11,612,672 | ||||||
Derivative liabilities [Note 8] | 537,318 | 352,402 | ||||||
Operating lease liability [Note 10] | 1,061,795 | 1,120,018 | ||||||
TOTAL LIABILITIES | 18,710,097 | 18,822,706 | ||||||
STOCKHOLDERS' EQUITY (DEFICIENCY) | ||||||||
Preferred stock, $0.001 par value, 10,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 1 share issued and outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] | 1 | 1 | ||||||
Preferred stock, $0.001 par value, 20,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 6,872 and 7,201 preferred shares issued and outstanding as at June 30, 2022 and as at March 31, 2022, respectively [Note 9] | 8 | 7 | ||||||
Preferred stock | 1 | 1 | ||||||
Common stock, $0.001 par value, 125,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively. Issued and outstanding common shares: 50,219,034 and 49,810,322 as at June 30, 2022 and March 31, 2022, respectively, and exchangeable shares of 1,466,718 and 1,466,718 outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] | 51,685 | 51,277 | ||||||
Shares to be issued 95,515 and 123,817 shares of common stock as at June 30, 2022 and March 31, 2022, respectively) [Note 9] | 72,299 | 102,299 | ||||||
Additional paid-in-capital | 91,912,772 | 91,507,478 | ||||||
Accumulated other comprehensive loss | (535,653 | ) | (768,656 | ) | ||||
Accumulated deficit | (98,061,531 | ) | (93,037,142 | ) | ||||
Total stockholders' equity (deficiency) | (6,560,418 | ) | (2,144,736 | ) | ||||
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY | 12,149,679 | 16,677,970 | ||||||
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE MONTHS ENDED JUNE 31, 2022 AND 2021 (unaudited)
(Expressed in US Dollars)
| 3 Months Ended June 30, 2022 | 3 Months Ended June 30, 2021 | |||||||
| $ | $ | |||||||
REVENUE | 2,056,052 | 1,764,110 | ||||||
Cost of Revenue | 830,923 | 525,426 | ||||||
GROSS PROFIT | 1,225,129 | 1,238,684 | ||||||
EXPENSES | ||||||||
General and administrative expenses [Notes 8, 9 and 10] | 4,881,003 | 3,652,203 | ||||||
Research and development expenses | 821,176 | 588,997 | ||||||
TOTAL OPERATING EXPENSES | 5,702,179 | 4,241,200 | ||||||
Other (income)/expense [Note 8] [Note 9] | - | (8,782 | ) | |||||
Loss upon convertible promissory notes conversion | 50,908 | 28,215 | ||||||
Accretion and amortization expenses [Note 5] [Note 6] | 50,070 | 2,335,167 | ||||||
Change in fair value of derivative liabilities [Note 8] | 198,224 | 298,983 | ||||||
NET LOSS BEFORE INCOME TAXES | (4,776,252 | ) | (5,656,099 | ) | ||||
Income taxes | - | - | ||||||
NET LOSS BEFORE DIVIDENDS | (4,776,252 | ) | (5,656,099 | ) | ||||
Less: Preferred Stock Dividends | 248,137 | 241,264 | ||||||
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | (5,024,389 | ) | 5,897,363 | |||||
Translation adjustment | 233,003 | 6,560 | ||||||
COMPREHENSIVE LOSS | (4,791,386 | ) | (5,890,803 | ) | ||||
LOSS PER SHARE, BASIC AND DILUTED | (0.098 | ) | (0.151 | ) | ||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | 51,440,944 | 39,095,637 | ||||||
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)
(Expressed in US Dollars)
| Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | |||||||
| $ | $ | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | (4,776,252 | ) | (5,656,099 | ) | ||||
Adjustments to reconcile net loss to net cash used in operations | ||||||||
Stock based compensation | 149,190 | 155,851 | ||||||
Issuance of shares for services | 7,051 | - | ||||||
Issuance of warrants for services | 77,414 | 151,897 | ||||||
Accretion and amortization expenses | - | 2,335,167 | ||||||
Change in fair value of derivative liabilities | 198,224 | 298,983 | ||||||
Loss on debt | 50,908 | 28,213 | ||||||
Property, plant and equipment depreciation | 1,488 | - | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 179,758 | (401,818 | ) | |||||
Inventory | (588,130 | ) | 92,694 | |||||
Deposits and other receivables | (4,312 | ) | (86,221 | ) | ||||
Accounts payable and accrued liabilities | 416,047 | 399,937 | ||||||
Net cash used in operating activities | (4,288,164 | ) | (2,681,396 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
property, plant and equipment | - | - | ||||||
Net cash used in investing activities | - | - | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Issuance of common shares, net | - | - | ||||||
Issuance of preferred shares, net | - | - | ||||||
Redemption of preferred shares | (328,904 | ) | - | |||||
Exercise of warrants for cash | - | 146,250 | ||||||
Federally guaranteed loans | - | 499,900 | ||||||
Proceeds from (repayment to) convertible notes, net | - | - | ||||||
Proceeds from (repayment to) convertible debentures, net | - | 139,780 | ||||||
Issuance of shares from uplisting | - | - | ||||||
Proceeds pursuant to term loan, net | 50,070 | - | ||||||
Preferred Stock Dividend | (516,817 | ) | (204,842 | ) | ||||
Net cash provided by financing activities | (795,651 | ) | 581,088 | |||||
Effect of foreign currency translation | 224,860 | 100,334 | ||||||
Net increase (decrease) in cash during the period | (5,083,815 | ) | (1,999,974 | ) | ||||
Cash, beginning of period | 12,066,929 | 2,201,562 | ||||||
Cash, end of period | 7,207,974 | 201,588 | ||||||
SOURCE: Biotricity, Inc.
View source version on accesswire.com:
https://www.accesswire.com/712089/Biotricity-Reports-Financial-Results-for-Fiscal-2023-First-Quarter
